Company Profile · Healthcare

Solventum Corp.

SOLV · US
Exchange
US
Country
USA
IPO date
Mar 26, 2024
Employees
20,584
Current Price
$75.43
Live · Jun 18, 2026
Fair Buy
≤ $65
Margin-of-safety entry
Baillie Growth Score
39/100
Weak
Intrinsic Value · Three-Tier Range Current price $75.43 Live · Within the fair intrinsic-value range

Composite valuation range · conservative $50–$65 / fair $70–$90 / optimistic $105–$135. At $75.43, Within the fair intrinsic-value range.

At publication $74.95 (May 30, 2026)

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.

Market cap$13.32B
Revenue (TTM)$8.26B
EBITDA$1.12B
Profit margin17.33%
ROE34.79%
P/E (TTM)9.41
Forward P/E11.74
PEG1.22
EPS$8.17
52-week range$62.38 – $88.20
Analyst target$82.15
Analyst rating3.3 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.